Challenges in the treatment of cystic fibrosis in the era of CFTR modulatorsAuthors' replyUse of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele a systematic review and meta-analysisDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY) results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsAssessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.

IF 2.9 4区医学 Q2 RESPIRATORY SYSTEM

Jornal Brasileiro De Pneumologia Pub Date : 2024-05-27 DOI:10.36416/1806-3756/e20240107

Caroline Jacoby Schmidt, Laura Silveira de Moura, Paulo de Tarso Roth Dalcin, Bruna Ziegler

引用次数: 0

CFTR调节剂时代囊性纤维化治疗面临的挑战作者回复在囊性纤维化且至少有一个F508del等位基因的患者中使用eexacaftor+tezacaftor+ivacaftor的系统综述和荟萃分析在接受调节剂治疗的囊性纤维化患者中停用与继续使用高渗盐水或dornase alfa（SIMPLIFY）两项平行、多中心、开放标签、随机对照、非劣效性试验的结果评估停用高渗盐水对用力呼气容积降低者的安全性多中心、开放标签、随机对照、非劣效试验评估停用高渗盐水对 Elexacaftor/Tezacaftor/Ivacaftor 治疗后 1 秒内用力呼气容积降低者的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Jornal Brasileiro De Pneumologia RESPIRATORY SYSTEM-

CiteScore

3.50

自引率

14.80%

发文量

118

审稿时长

20 weeks

期刊介绍： The Brazilian Journal of Pulmonology publishes scientific articles that contribute to the improvement of knowledge in the field of the lung diseases and related areas.